TRENDS OF INFLAMMATORY BOWEL DISEASE BURDEN IN THE UNITED STATES (1990-2019), PROJECTIONS OF DEATHS TO 2040: INSIGHTS FROM THE 2019 GLOBAL BURDEN OF DISEASE STUDY

Rahul Patel,Vivek Roy,Suraj Kunhipurayil,Krina Manojbhai Patel,Samar Elassar,Vani Sojitra,Hardik Dineshbhai Desai
DOI: https://doi.org/10.1093/ibd/izae020.086
2024-01-25
Inflammatory Bowel Diseases
Abstract:Abstract BACKGROUND Inflammatory Bowel Disease (IBD) ranks as the 9th primary cause of deaths and 7th for disabilities among all digestive diseases, affecting over 3 million Americans with a continuous upsurge. METHOD Utilizing the Global Burden of Disease methodology, we evaluated the prevalence, incidence, mortality, and Disability Adjusted Life Years (DALYs) of IBD from 1990 to 2019 in the U.S. based on age, sex, and year via a standardized statistical model. Furthermore, we forecasted deaths and Years of Life Lost (YLLs) up to 2040 through a regression framework. RESULTS IBD prevalence showed a decline from 982,981 (95%UI: 846,832-1,129,782) in 1990 to 762,889 (712,356-813,653) in 2019. From 1990-2019, the total annual incidence reduced by 12% (4-18), while deaths surged by 172% (81-199), and DALYs increased by 16% (2-34) (Figure 1). The Age-Standardized Rate (ASR) for mortality rose from 0.62 (0.60-0.82) per 100,000 cases in 1990 to 1.02 (0.8-1.11) in 2019. In raw counts, Nevada saw the most significant rise in incidence (87%), deaths (486%), and DALYs (174%) from 1990-2019. Based on ASR, West Virginia and Kentucky led in mortality increases with 87% and 83% respectively (Figure 2). In 2019, the age group 80-84 reported the highest deaths (848), while ages 25-29 saw the most significant incidence (8429), and ages 60-64 the highest DALYs (20933). Comparing genders, females had a steeper increase in DALYs (17% vs. 13% for males), whereas males saw a higher rise in deaths (181% vs. 167% for females) between 1990-2019. By 2040, IBD-related age-standardized mortality rates are predicted to climb by 0.9 per 100,000. CONCLUSION In 2019, IBD was responsible for 4.56% of all digestive disease deaths. Highlighting a comprehensive challenge for the U.S. healthcare, IBD's impact is not just clinical or economic but also profoundly psychosocial. Emphasizing early detection, cutting-edge treatments, and comprehensive patient support is crucial to lessen the severe implications of IBD in the U.S.
gastroenterology & hepatology
What problem does this paper attempt to address?
The paper primarily explores the incidence and prevalence trends of Inflammatory Bowel Disease (IBD) at different epidemiological stages globally. Specifically, the study aims to collect real-world data through meta-analysis to describe the incidence and prevalence of IBD in various regions worldwide at different epidemiological stages. The research background points out that the rising trends in IBD incidence and prevalence observed in early industrialized regions are now also appearing in newly industrialized and developing regions. The epidemiology of IBD is divided into three stages: 1. **Emergence stage** (low incidence and prevalence); 2. **Acceleration stage** (rapid increase in incidence); 3. **Accumulation stage** (incidence stabilizes, prevalence rapidly increases). The research methods include updating two previous systematic reviews and searching multiple databases (such as MEDLINE, Embase, PubMed, and Web of Science) to identify population-based studies reporting the incidence or prevalence of Crohn’s disease (CD) and Ulcerative colitis (UC). The research team conducted an international secondary review of the included studies. Meta-analysis was used to determine the pooled incidence and prevalence at each epidemiological stage and their 95% confidence intervals. The results indicate that the pooled incidence of CD and UC increased from 0.28 and 0.57 per 100,000 person-years in the first stage to 9.34 and 14.07 in the third stage, respectively. Similarly, the pooled prevalence of CD and UC increased from 1.96 and 6.35 per 100,000 in the first stage to 186.18 and 255.92 in the third stage, respectively. Subgroup analysis confirmed significant differences in the incidence and prevalence of CD and UC between different epidemiological stages. The discussion section emphasizes that this is the most comprehensive systematic review to date on the incidence and prevalence of IBD, highlighting the growing burden of IBD across three distinct epidemiological stages globally.